Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Stockholders Equity of $8.65 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +964.2% in Stockholders Equity from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2018 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $5.00 million | Q4 2018: $5.00 million | Q2 2019: $5.00 million | Q3 2019: $5.00 million | Q4 2019: $5.00 million | Q1 2020: $5.00 million | Q1 2020: -$7.56 million | Q2 2020: $5.00 million | Q2 2020: -$8.41 million | Q3 2020: $5.00 million | Q3 2020: -$8.65 million | Q4 2020: $5.00 million | Q1 2021: $4.52 million | Q2 2021: $34.52 million | Q3 2021: $32.27 million | Q1 2022: $21.36 million | Q2 2022: $16.06 million | Q1 2023: $1.61 million | Q2 2023: -$1.82 million | Q3 2023: -$12.81 million | Q1 2024: -$1.35 million | Q2 2024: -$6.04 million | Q3 2024: -$9.98 million | Q1 2025: -$4.46 million | Q2 2025: -$459.1 thousand | Q3 2025: $4.55 million.
- Over the full 14 years of available data (2018 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Stockholders Equity has grown by 245.0%.
- Historical annual values: Fiscal year 2025: $8.65 million | Fiscal year 2024: $812.6 thousand | Fiscal year 2023: $5.72 million | Fiscal year 2023: -$12.81 million | Fiscal year 2023: -$1.82 million | Fiscal year 2023: $1.61 million | Fiscal year 2022: $8.39 million | Fiscal year 2022: $17.56 million | Fiscal year 2021: $28.69 million | Fiscal year 2020: $5.47 million | Fiscal year 2020: $5.00 million | Fiscal year 2019: -$6.81 million | Fiscal year 2019: $5.00 million | Fiscal year 2018: -$5.96 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: